Potential of early intervention in CLL: should the watch-and-wait strategy remain standard?

Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the potential of early intervention in chronic lymphocytic leukemia (CLL), highlighting that the watch-and-wait strategy remains the standard of care, as studies such as CLL12 (NCT02863718) have shown no overall survival benefit with early intervention using treatments like ibrutinib. Prof. Danilov notes that early treatment can increase exposure to adverse events, but acknowledges the importance of ongoing studies like the EVOLVE CLL/SLL study (NCT04269902), which investigates early intervention with venetoclax and obinutuzumab in high-risk CLL patients. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.